Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of IV TP-271 in Healthy Adults
NCT02724085Phase 1Completed
- Sponsor
- Tetraphase Therapeutics
- Start
- Dec 2015
- Primary completion
- Sep 2016
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TP-271 in pneumonia (7 cohorts), sponsored by Tetraphase Therapeutics. Primary endpoints: Adverse Events at 39 days, Physical Examinations at 39 days and 3 more. Started Dec 2015; status: completed.
02
Drugs
TP-271
03
Conditions
pneumonia
Beyond the preview
Go deeper on NCT02724085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02724085.